SCHEMBL25035166

SCHEMBL25035166

Cc1cccc(-c2ccc(OCc3ccccc3)nc2OCc2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.43
SQOR Q9Y6N5 1/20 0.43
MAOB P27338 1/20 0.43
ADORA1 P30542 1/20 0.42
PDE5A O76074 1/20 0.41
GRM5 P41594 1/20 0.41
MCL1 Q07820 1/20 0.41
BAK1 Q16611 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
FFAR1 O14842 3/20 0.39
FFAR4 Q5NUL3 1/20 0.39
GABRG2 P18507 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30475448 1.00 L3MBTL1 (0.43) L3MBTL1SQORMAOBADORA1PDE5A
SCHEMBL25819197 0.88 L3MBTL1 (0.44) L3MBTL1SQORMAOBADORA1PDE5A
SCHEMBL30475462 0.85 SQOR (0.44) L3MBTL1SQORADORA1PDE5AGRM5
SCHEMBL25035127 0.85 SQOR (0.44) L3MBTL1SQORADORA1PDE5AGRM5
SCHEMBL31105721 0.85 L3MBTL1 (0.47) L3MBTL1SQORMAOBPDE5AGRM5
SCHEMBL31213301 0.84 MAOB (0.49) SQORMAOBPDE5AGRM5MEN1
SCHEMBL24873214 0.84 GABRG2 (0.56) L3MBTL1SQORMAOBPDE5AGRM5
SCHEMBL30112435 0.84 GABRG2 (0.56) L3MBTL1SQORMAOBPDE5AGRM5
SCHEMBL31607924 0.82 CYP4F2 (0.51) SQORPDE5AGRM5MAPK1TDP1
SCHEMBL26641525 0.82 CYP4F2 (0.51) SQORPDE5AGRM5MAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023018238-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 L3MBTL1 964/4885SQOR 3787/4885MAOB 3956/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 L3MBTL1 2040/4885SQOR 2802/4885MAOB 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.